

Roberto A Calle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754873/publications.pdf>

Version: 2024-02-01

30
papers

1,399
citations

430874

18
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

1976
citing authors

#	ARTICLE	IF	CITATIONS
1	A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. <i>Cell Metabolism</i> , 2016, 23, 427-440.	16.2	377
2	Once-a-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1762-1772.	4.4	106
3	ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. <i>Nature Medicine</i> , 2021, 27, 1836-1848.	30.7	97
4	Diacylglycerol Production, Ca ²⁺ Influx, and ProteinKinase C Activation in Sustained Cellular Responses*. <i>Endocrine Reviews</i> , 1995, 16, 649-681.	20.1	96
5	Modulation of 11 β -Hydroxysteroid Dehydrogenase (11 β HSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11 β HSD1 Inhibitor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 550-556.	3.6	86
6	Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1051-1063.	2.4	79
7	GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. <i>Cell Metabolism</i> , 2020, 32, 938-950.e6.	16.2	70
8	Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice. <i>PLoS ONE</i> , 2015, 10, e0119104.	2.5	55
9	Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β -Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. <i>Diabetes Care</i> , 2016, 39, 1602-1613.	8.6	47
10	FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. <i>Scientific Reports</i> , 2015, 5, 11382.	3.3	45
11	Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation. <i>Molecular and Cellular Endocrinology</i> , 2001, 173, 87-94.	3.2	34
12	Arginine is preferred to glucagon for stimulation testing of β -cell function. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E720-E727.	3.5	34
13	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. <i>Nature Medicine</i> , 2022, 28, 430-432.	30.7	33
14	Fibroblast Growth Factor 21 Improves Insulin Sensitivity and Synergizes with Insulin in Human Adipose Stem Cell-Derived (hASC) Adipocytes. <i>PLoS ONE</i> , 2014, 9, e111767.	2.5	28
15	Mechanism of angiotensin II-induced phospholipase D activation in bovine adrenal glomerulosa cells. <i>Molecular and Cellular Endocrinology</i> , 2002, 192, 7-16.	3.2	27
16	Elevated Serum Sorbitol and not Fructose in Type 2 Diabetic Patients. <i>Biomarker Insights</i> , 2010, 5, BMI.S4530.	2.5	27
17	Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 506-513.	4.4	26
18	Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. <i>Med</i> , 2021, 2, 800-813.e3.	4.4	24

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2608-2616.	4.4	20
20	Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21 Antibody Protein Conjugate. <i>Drug Metabolism and Disposition</i> , 2015, 43, 803-811.	3.3	18
21	Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. <i>Scientific Reports</i> , 2018, 8, 4241.	3.3	17
22	Elevated K ⁺ induces myristoylated alanine-rich C-kinase substrate phosphorylation and phospholipase D activation in glomerulosa cells. <i>Molecular and Cellular Endocrinology</i> , 2001, 184, 65-76.	3.2	15
23	Characterization and Phospholipase D Mediation of the Angiotensin II Priming Response in Adrenal Glomerulosa Cells. <i>Endocrinology</i> , 2007, 148, 585-593.	2.8	11
24	Phorbol ester increases mitochondrial cholesterol content in NCI H295R cells. <i>Molecular and Cellular Endocrinology</i> , 2008, 296, 53-57.	3.2	10
25	Angiotensin II priming of aldosterone secretion with agents that enhance Ca ²⁺ influx. <i>Molecular and Cellular Endocrinology</i> , 2001, 177, 61-70.	3.2	9
26	Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of a Novel Sorbitol Dehydrogenase Inhibitor in Healthy Participants. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 521-530.	2.0	3
27	Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, e45-e49.	2.8	3
28	The effects of ertugliflozin on β -cell function: Pooled analysis from four phase 3 randomized controlled studies. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2267-2275.	4.4	2
29	TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT. , 0, , 35-61.		0
30	Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 94-99.	1.1	0